September 23, 2019 by Johnson Paul
The latest market report published by Credence Research, Inc. “Photopheresis Products Market By Type (Closed System, Open System), By Therapeutic Area (Cutaneous T-Cell Lymphoma, Solid Organ Transplant Rejections, Autoimmune Diseases, Graft Versus Host Diseases) - Growth, Future Prospects, Competitive Analysis, 2018 - 2026,” The global market for photopheresis Products was valued at US$ 257 million in 2017 and is expected to reach US$ 418.56 million by 2026, increasing to CAGR by 5.5 per cent from 2018 to 2026.
Photopheresis uses apheresis and photodynamic therapy to treat blood with a photosensitizing agent followed by treatment with defined wavelengths of light. In photopheresis, buffy coat (WBC and platelets) is separated from the whole blood and then chemically handled with8-methoxypsoralene and subjected to ultraviolet-A light. As the incidence of autoimmune diseases, ongoing research and development activities are being conducted to develop the most suitable treatments. Photopheresis is also seen as a promising therapy for transplant rejection, graft versus host disease, cutaneous T-cell lymphoma, and autoimmune illnesses.
Browse the full report at https://www.credenceresearch.com/report/photopheresis-market
Based on product kinds, the worldwide market for photopheresis products is segmented into closed systems and open systems. In 2017, the closed systems segment retained the biggest market share owing to its advanced technology and the increasing preference of patients and physicians for the use of closed systems for photopheresis treatment. The popularity of closed systems is also ascribed to their flexible use in all the therapeutic fields considered.
Among the therapeutic fields considered, i.e. autoimmune illnesses, graft versus host illness, cutaneous T-cell lymphoma and strong organ transplant rejection, photopheresis has the greatest application in autoimmune diseases. Graft versus host disease was identified as the biggest segment in 2017 owing to variables such as increasing allogeneic transplantation, a big number of chronic graft versus host disease patients, the evolution of diagnostic techniques and a consistent increase in research and development attempts.
Geographically, North America is the largest regional market for photopheresis. Presence of large pool of autoimmune disease patients, greater awareness in general population, well-structured reimbursement scenario and widespread presence of market incumbents contribute to the dominant position of North America. On the other hand, Asia Pacific is estimated to be the fastest progressing market for photopheresis. Rapidly developing healthcare infrastructure, significantly large patient pool and improving diagnostics front are the key growth drivers of Asia Pacific market.
Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/58735
The global photopheresis market is highly competitive and diversified, characterized by the presence of large number of players. The domination of the key players is subject to their product diversity and core competencies. Some of the major players operating in the global photopheresis market are Terumo Corporation, Malinckrodt Pharmaceuticals, Fresenius Kabi AG, Macopharma, Haemonetics Corporation, and others.
Key Market Movements:
By Type (2016–2026; US$ Mn)
By Therapeutic Area (2016–2026; US$ Mn)
By Geography Segment